Association of CCR5-59029 A/G and CCL3L1 Copy number polymorphism with HIV type 1 transmission/progression among HIV type 1-seropositive and repeatedly sexually exposed HIV type 1-seronegative north Indians

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1149-1156

  Rathore, Anurag ^a   Chatterjee, Animesh ^a   Sivarama, P ^b   Yamamoto, Naohiko ^c   Singhal, Pradeep K ^d   Dhole, Tapan N ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b AIDS Counseling and Treatment Center   (India)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Professional Biotech Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE INTERACTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; CHEMOKINES, CC; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DNA COPY NUMBER VARIATIONS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; INDIA; MALE; RECEPTORS, CCR5; SEXUAL BEHAVIOR;

EID: 71949110378     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0019     Document Type: Article

References (32)

1. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, and Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
2. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, and Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
3. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, and Gallo RC: Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998:95:3851-3856.
4. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, and O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
5. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR, 3rd HIV Network for Prevention Trials Vaccine Preparedness Protocol Team: Homozygous and heterozygous CCR5-delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-481.
6. Thomas SM, Tse DB, Ketner DS, Rochford G, Meyer DA, Zade DD, Halkitis PN, Nádas A, Borkowsky W, and Marmor M: CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men. AIDS 2006;20:1879-1883.
7. Kaur G, Singh P, Rapthap CC, Kumar N, Vajpayee M, Sharma SK, Wanchu A, and Mehra NK: Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol 2007;68:454-461.
8. Verma R, Gupta RB, Singh K, Bhasin R, Anand Shukla A, Chauhan SS, and Luthra K: Distribution of CCR5delta32, CCR2-64I and SDF1-3'′A and plasma levels of SDF-1 in HIV-1 seronegative North Indians. J Clin Virol 2007;38:198-203.
9. Suresh P, Wanchu A, Sachdeva RK, and Bhatnagar A: Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. J Clin Immunol 2006;26: 476-484.
10. Rathore A, Chatterjee A, Sivarama P, Yamamoto N, and Dhole TN: Role of homozygous DC-SIGNR 5=5 tandem repeat polymorphism in HIV-1 exposed seronegative north Indian individuals. J Clin Immunol 2008;28(1):50-57.
11. Arenzana-Seisdedos F and Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006;18:387-403.
12. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, and Murphy PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998;352:866-870.
13. Knudsen TB, Kristiansen TB, Katzenstein TL, and Eugen- Olsen J; Copenhagen AIDS Study Group: Adverse effect of the CCR5 promoter-2459A allele on HIV-1 disease progression. J Med Virol 2001;65:441-444.
14. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, and Stewart GJ: CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS 2000;14: 103-108.
15. Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, Zimmerman PA, and Lederman MM: CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 2003;108:234-240.
16. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, Sakchalathorn P, Hwangbo Y, Greene B, Zhu T, and McElrath MJ: Combined effect of CCR5-delta32 heterozygosity and the CCR5 promoter polymorphism-2459 A=Gon CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005;79:11677-11684.
17. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, and Ahuja SK: The influence of CCL3L1 genecontaining segmental duplications on HIV-1=AIDS susceptibility. Science 2005;307:1434-1440.
18. Townson JR, Barcellos LF, and Nibbs RJ: Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 2002;32:3016-3026.
19. Nakajima T, Ohtani H, Naruse T, Shibata H, Mimaya JI, Terunuma H, and Kimura A: Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia. Immunogenetics 2007;59:793-798.
20. Shao W, Tang J, Song W, Wang C, Li Y, Wilson CM, and Kaslow RA: CCL3L1 and CCL4L1: Variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection. Genes Immun 2007;8:224-231.
21. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, and Ahuja SK: CCL3L1 and CCR5 influence cell-mediated immunity and affect HIVAIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007;8:1324-1336.
22. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Samantha L, Donninger SL, Gray GE, Sherman GG, Coovadia AH, and Kuhn L: Host CCL3 genotype influences the development and maintenance of HIV-specific T cell responses associated with control of infection. 1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity, 10-13 June 2007, Budapest, Hungary. Tiemessen1, Budapest Hungary poster.
23. McNicholl JM, Lal RB, and Kaslow R: Human immunodeficiency virus (HIV) infection. In: Encyclopedia of the Human Genome (Cooper DN, Ed.). Nature Publishing Group, New York, 2003.
24. Vajpayee M, Kaushik S, Sreenivas V, Wig N, and Seth P: CDC staging based on absolute CD4 count and CD4 percentage in an HIV-1 infected Indian population: Treatment implication. Clin Exp Immunol 2005;141:485.
25. An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien SJ, and Winkler CA: Influence of CCR5 promoter haplotypes on AIDS progression in African- Americans. AIDS 2000;14:2117-2122.
26. Easterbrook PJ, Rostron T, Ives N, Troop M, Gazzard BG, and Rowland-Jones SL: Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect Dis 1999;18:1096-1105.
27. Wasik TJ, Smoleń J, Kruszyń ski P, Bratosiewicz-Wasik J, and Beniowski M: Effects of CCR5-delta32, CCR2-64I and SDF-1-3'′A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population. Wiad Lek 2005;58:500-507.
28. McKinney C, Merriman ME, Chapman PT, Gow PJ, Harrison AA, Highton J, Jones PB, McLean L, O'Donnell JL, Pokorny V, Spellerberg M, Stamp L, Willis J, Steer S, and Merriman T: Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann Rheum Dis 2007;67(3):409-413.
29. Pilotti E, Elviri L, Vicenzi E, and Bertazzoni U: Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007;109:1850-1856.
30. Suresh P, Wanchu A, Bhatnagar A, Sachdeva RK, and Sharma M: Spontaneous and antigen-induced chemokine production in exposed but uninfected partners of HIV type 1-infected individuals in North India. AIDS Res Hum Retroviruses 2007;23:261-268.
31. Deeks SG and Walker BD: Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27(3):406-416.
32. Lama J and Planelles V: Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 2007;4:52.